HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Early rheumatologist evaluation of RA improves outcomes

The Journal of Musculoskeletal Medicine, The Journal of Musculoskeletal Medicine Vol 28 No 2, Volume 28, Issue 2

For patients with rheumatoid arthritis (RA), a shorter time to assessment by a rheumatologist is associated with longer disease-modifying antirheumatic drug (DMARD)-free remission times and less joint destruction.

For patients with rheumatoid arthritis (RA), a shorter time to assessment by a rheumatologist is associated with longer disease-modifying antirheumatic drug (DMARD)-free remission times and less joint destruction. However, patients with early arthritis who have a diagnosis of RA experience one of the longest delays and only one-third are assessed within the “window of opportunity.”

van der Linden and associates evaluated patient, general practitioner (GP), and rheumatologist delay in 1674 patients with early arthritis; 598 had RA. The latter patients were evaluated for the relationships among total delay, achievement of DMARD-free remission, and rate of joint destruction over 6 years.

Among patients with early arthritis, the average patient, GP, and rheumatologist delays were 2.4, 8.0, and 13.7 weeks, respectively. Among persons with RA, the delay was longest at 18 weeks; most (67%) of these patients were seen 12 weeks or longer after receiving the diagnosis, and they had a hazard ratio of 1.87 for failure to achieve DMARD-free remission. They also had 1.3 times more joint destruction over 6 years than persons seen before 12 weeks.

The authors noted that diminishing the delay in assessment by a rheumatologist will be crucial to further improvement in disease outcomes.